EyePoint Pharmaceuticals stock analysis
EyePoint Pharmaceuticals (PV3B) Stock Price & Analysis
PV3B Stock Chart & Stats
- Day’s Range
- EUR 0.25 - EUR 0.25
- 52-Week Range
- EUR 0.25 - EUR 16.13
- Previous Close
- EUR 0.28
- Volume
- N/A
- Average Volume (3M)
- 58
- Market Cap
- EUR 28.21M
- Enterprise Value
- EUR 195.37M
- Total Cash (Recent Filing)
- EUR 118.21M
- Total Debt (Recent Filing)
- EUR 19.12M
- Price to Earnings (P/E)
- ―
- Beta
- 1.57
- Next Earnings
- Mar 04, 2027 (Est.)
- EPS Estimate
- -0.63
- Next Dividend Ex-Date
- N/A
- Dividend Yield
- N/A
Bulls Say, Bears Say
Bulls Say
DME Clinical Signal
Positive Phase II DME results provide a differentiated clinical foundation for the company’s central program. Equivalent vision improvement, better anatomical measures, and fewer supplemental injections could support adoption if these benefits are reproduced in pivotal trials.
Sustained-Release Platform
The sustained-release delivery approach addresses treatment burden, a persistent challenge in retinal disease care. Six-month redosing and practical administration could improve adherence and physician appeal, while the multi-mechanism profile may support differentiation across targeted indications.
Cost Structure Reset
The restructuring aligns operating expenses with a narrower DME strategy and should materially reduce the recurring cash cost of development. These savings can extend financial flexibility, concentrate resources on the lead program, and improve execution discipline over the next several quarters.
Bears Say
Wet AMD Phase III Failure
Failure of both pivotal wet AMD trials removed a major development pathway and led to program discontinuation. This narrows the company’s clinical portfolio, eliminates near-term regulatory optionality in that indication, and leaves DME as the principal driver of future value.
Persistent Cash Burn
Deeply negative operating and free cash flow indicate that the business is not currently self-funding its development activities. Continued cash consumption can require external financing or partnerships, potentially limiting strategic flexibility and increasing execution pressure around clinical milestones.
Runway And Financing Risk
The stated runway does not clearly cover the period through the next major DME data readout. Unless additional savings, financing, or business development proceeds are secured, funding needs could arise before pivotal results clarify the program’s commercial and regulatory prospects.
PV3B FAQ
What was EyePoint Pharmaceuticals’s price range in the past 12 months?
What is EyePoint Pharmaceuticals’s market cap?
When is EyePoint Pharmaceuticals’s upcoming earnings report date?
How were EyePoint Pharmaceuticals’s earnings last quarter?
Is EyePoint Pharmaceuticals overvalued?
Does EyePoint Pharmaceuticals pay dividends?
What is EyePoint Pharmaceuticals’s EPS estimate?
How many shares outstanding does EyePoint Pharmaceuticals have?
What happened to EyePoint Pharmaceuticals’s price movement after its last earnings report?
Which hedge fund is a major shareholder of EyePoint Pharmaceuticals?
What is the TipRanks Smart Score and how is it calculated?
EyePoint Pharmaceuticals Stock Smart Score
Company Description
EyePoint Pharmaceuticals
EyePoint Pharmaceuticals, Inc. is a pharmaceutical firm dedicated to the creation and marketing of ophthalmic solutions for various eye ailments. Its operations span the United States, China, and the United Kingdom. Among its commercialized product portfolio are ILUVIEN, an injectable, sustained-release micro-insert designed to treat diabetic macular edema, and YUTIQ, an intravitreal implant containing fluocinolone acetonide, which targets chronic non-infectious uveitis impacting the posterior segment of the eye. The company also offers DEXYCU, a dexamethasone intraocular suspension, utilized to manage post-operative ocular inflammation, such as that occurring after cataract surgery. Looking ahead, EyePoint is actively developing several pipeline therapies. This includes EYP-1901, a novel, bioerodible tyrosine kinase inhibitor currently formulated for twice-yearly administration, which is under development for conditions like wet age-related macular degeneration, diabetic retinopathy, and retinal vein occlusion. Additionally, YUTIQ50 is being advanced as a treatment for chronic non-infectious uveitis affecting the posterior region of the eye. To bolster its market reach and development efforts, the company maintains strategic alliances with entities such as Alimera Sciences, Inc., Bausch & Lomb, OncoSil Medical UK Limited, Ocumension Therapeutics, and Equinox Science, LLC. Furthermore, a commercial collaboration with ImprimisRx PA, Inc. specifically focuses on the joint promotion of DEXYCU for inflammation following ocular surgery. Incorporated in 1987, the organization was previously known as pSivida Corp. before officially rebranding as EyePoint Pharmaceuticals, Inc. in March 2018. Its corporate headquarters are situated in Watertown, Massachusetts.
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Jay S. Duker
- Employees
- 214
- Website
- www.eyepoint.bio
- Address
- 480 Pleasant Street, Watertown, MA, 02472, US
EyePoint Pharmaceuticals (PV3B) Earnings & Revenues
PV3B Earnings Call
Earnings Call SentimentNeutral
The call conveyed significant disappointment following the failure of both Phase III wet AMD trials and the resulting program discontinuation and workforce reduction. However, management expressed confidence in DURAVYU's DME opportunity, supported by the VERONA data, the drug's multi-mechanism rationale, extensive safety experience, ongoing COMO and CAPRI studies, and planned cost reductions. The outlook was mixed, with meaningful clinical and financial execution risks balanced by a focused DME strategy and several stated efficacy and durability advantages.
View all DE:PV3B earnings summariesPV3B Stock 12 Month Forecast
Average Price Target
Technical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 5 | 0 | 17 |
| Technical Analysis | 5 | 0 | 5 |
| Moving Averages | 0 | 0 | 12 |










